title: Glycoprotein 130 regulates bone turnover and bone size by distinct downstream signaling pathways.
abstract: The gp130-dependent cytokines, which signal through at least two intracellular pathways, regulate osteoclast and osteoblast formation. To define their roles in regulating bone mass, we analyzed mice in which gp130 signaling via either the signal transducer and activator of transcription (STAT) 1/3 (gp130(DeltaSTAT/DeltaSTAT)) or SHP2/ras/MAPK (gp130(Y757F/Y757F)) pathway was attenuated. In gp130(DeltaSTAT/DeltaSTAT) mice, trabecular bone volume (BV/TV) and turnover were normal, but bone length was reduced by premature growth plate closure, indicating an essential role for gp130-STAT1/3 signaling in chondrocyte differentiation. In contrast, while bone size was normal in gp130(Y757F/Y757F) mice, BV/TV was reduced due to high bone turnover, indicated by high osteoclast surface/bone surface (OcS/BS) and osteoblast surface/bone surface (ObS/BS). Furthermore, generation of functional osteoclasts from bone marrow of gp130(Y757F/Y757F) mice was elevated, revealing that while gp130 family cytokines stimulate osteoclastogenesis through the osteoblast lineage, gp130, via SHP2/Ras/MAPK, inhibits osteoclastogenesis in a cell lineage-autonomous manner. Genetic ablation of IL-6 in gp130(Y757F/Y757F) mice exacerbated this osteopenia by reducing ObS/BS without affecting OcS/BS. Thus, while IL-6 is critical for high bone formation in gp130(Y757F/Y757F) mice, it is not involved in the increased osteoclastogenesis. In conclusion, gp130 is essential for normal bone growth and trabecular bone mass, with balanced regulation depending on selective activation of STAT1/3 and SHP2/ras/MAPK, respectively. Furthermore, the latter pathway can directly inhibit osteoclastogenesis in vivo.
authors.affiliation: Department of Medicine at St. Vincent's Hospital, The University of Melbourne, Fitzroy, Victoria, Australia. nsims@medstv.unimelb.edu.au
authors.forename: Natalie A
authors.initials: NA
authors.lastname: Sims
authors.forename: Brendan J
authors.initials: BJ
authors.lastname: Jenkins
authors.forename: Julian M W
authors.initials: JM
authors.lastname: Quinn
authors.forename: Akira
authors.initials: A
authors.lastname: Nakamura
authors.forename: Markus
authors.initials: M
authors.lastname: Glatt
authors.forename: Matthew T
authors.initials: MT
authors.lastname: Gillespie
authors.forename: Matthias
authors.initials: M
authors.lastname: Ernst
authors.forename: T John
authors.initials: TJ
authors.lastname: Martin
mesh_terms: D000818:Animals; D001851:Bone Diseases, Metabolic / Q000235:genetics / Q000378:metabolism; D001842:Bone and Bones / Q000378:metabolism* / Q000473:pathology; D004392:Dwarfism / Q000235:genetics / Q000378:metabolism; D006023:Glycoproteins / Q000235:genetics / Q000378:metabolism*; D015850:Interleukin-6 / Q000378:metabolism; D051379:Mice; D009154:Mutation; D015398:Signal Transduction / Q000502:physiology*
chemical_list: D006023:Glycoproteins; D015850:Interleukin-6; C480482:glycoprotein 130, human